Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of 8 weeks of treatment with MN-001 at 500 mg bid, 500 mg
once daily vs. placebo in patients with Interstitial Cystitis.